Successful Toxicology Results Pave Way for Phase 2 Trial
Filed with ASX · · 4 pages · English
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- First patient dosed in eye disease clinical trial
- Placement Supporting Document
- Successful Completion of $30m Placement
- Commencement of First Clinical Study in RP11
- Second Drug Program Progressing to Human Trials
Later from PYC Therapeutics
- PYC Receives FDA Fast Track Designation
- PYC Increases Ownership of VP-001 Program
- RP11 Clinical Trial Dosing Completed In Patient Cohort 1
- Safety Review Committee Approves Dose Escalation
- PYC-001 Effective In Both NHPs and Patient-Derived Models
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics